Welcome to our dedicated page for Kymera Therapeutics news (Ticker: KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics stock.
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is a biotechnology company harnessing the power of targeted protein degradation (TPD) to develop transformative treatments for previously untreatable diseases. Founded in 2016, and headquartered in Watertown, Massachusetts, Kymera is at the forefront of biotechnology, utilizing the body's innate protein recycling machinery to degrade disease-causing proteins rather than merely inhibiting them.
The company's pioneering platform, Pegasus™, leverages proprietary predictive modeling and an integrated degradation approach to address disease targets previously deemed intractable. This novel modality allows Kymera to target and degrade proteins involved in various critical pathways, including those in immunological diseases and oncology. Key drugs in their pipeline include:
- KT-474: An IRAK4 degrader currently in Phase 2 trials for immuno-inflammatory conditions.
- KT-333: A STAT3 degrader in Phase 1 trials, targeting hematological malignancies and solid tumors.
- KT-253: An MDM2 degrader undergoing Phase 1 trials, aimed at cancers with p53 pathway involvement.
- KT-621: A STAT6 degrader poised to enter Phase 1 trials, showing promising preclinical results for treating TH2-driven diseases like asthma and atopic dermatitis.
Kymera's achievements include successful partnerships with leading pharmaceutical companies such as Sanofi, ongoing collaborations with research institutions, and securing significant financial backing with over $745 million in cash reserves to support operations into 2027. The company's innovative approach and robust pipeline have earned it recognition as one of Boston’s top workplaces.
Kymera continues to make significant strides in drug discovery and development, with a focus on delivering highly effective, convenient oral therapies. Recent updates include positive preclinical and clinical data presentations at major medical conferences, highlighting the potential of their degradation technology to revolutionize treatment paradigms across various diseases.
For more information, visit Kymera Therapeutics or follow them on X (formerly Twitter) and LinkedIn.
Kymera Therapeutics (NASDAQ: KYMR) announced a virtual investor event scheduled for December 14, 2022, where they will share clinical updates on their Phase 1 trial of the IRAK4 degrader KT-474. This trial targets patients with hidradenitis suppurativa or atopic dermatitis. Additionally, the company will discuss its oncology pipeline developments. Kymera focuses on targeted protein degradation to develop innovative therapies for various diseases, leveraging its proprietary Pegasus platform.
Kymera Therapeutics (NASDAQ: KYMR) announced substantial developments in its clinical programs and financial status. The company completed the patient cohort of the KT-474 Phase 1 trial, focusing on autoimmune diseases, and is on track for regulatory submissions for KT-253. In Q3 2022, Kymera raised $150 million in private equity, closing with a cash balance of $596 million, projected to sustain operations into 2025. However, collaboration revenues fell to $9.6 million from $20.3 million year-over-year, contributing to a net loss of $43 million.
Kymera Therapeutics (NASDAQ: KYMR) appointed Dr. Victor Sandor to its Board of Directors on November 3, 2022, to leverage his extensive experience in biopharmaceutical clinical development. Dr. Sandor, previously Chief Medical Officer at Array BioPharma, is expected to enhance Kymera’s capabilities in advancing targeted protein degradation therapies. The company acknowledged the contributions of retiring board member Don Nicholson, PhD, who has served for five years. Kymera aims to capitalize on its Pegasus platform to develop innovative treatments for various diseases.
Kymera Therapeutics (NASDAQ: KYMR) will announce its Q3 2022 financial results on November 3, 2022, hosting a conference call at 8:30 a.m. ET. The company is also set to participate in several investor conferences, including:
- Credit Suisse Annual Healthcare Conference on November 9
- Stifel Healthcare Conference on November 15
- Piper Sandler Healthcare Conference from November 29 to December 1
- Bank of America Biotech Conference on December 7
Access the call at kymeratx.com.
Kymera Therapeutics (NASDAQ: KYMR) has completed dosing in Part C of its Phase 1 clinical trial for KT-474, aimed at treating hidradenitis suppurativa (HS) and atopic dermatitis (AD). This Phase 1 trial showcases positive pharmacokinetics and safety results. Concurrently, the company continues dose escalation for KT-333 and KT-413, both targeting cancer indications. Additionally, IND enabling studies for KT-253 are complete, with an expected IND filing by year-end. A webcast on December 14 will present further details on clinical data and development pipelines.
Kymera Therapeutics (NASDAQ: KYMR) announced on September 15, 2022, that the FDA has granted orphan drug designation for its candidate KT-333 to treat Cutaneous T-cell Lymphoma (CTCL). This marks the second orphan designation for KT-333, which is a first-in-class STAT3 degrader. Currently, no approved therapies specifically target this pathway in CTCL. The FDA's designation allows for various development incentives such as tax credits and seven-year marketing exclusivity upon approval. The ongoing Phase 1 trial for KT-333 evaluates its safety in patients with aggressive lymphomas.
Kymera Therapeutics (NASDAQ: KYMR) announced that its Co-Founder, President, and CEO, Nello Mainolfi, will participate in several upcoming investor conferences. Key events include the 2022 Wells Fargo Healthcare Conference on September 7 at 1:20 p.m. ET, the Morgan Stanley 20th Annual Global Healthcare Conference on September 14 at 8:00 a.m. ET, and the 2022 Guggenheim Nantucket Therapeutics Conference on September 28 at 2:15 p.m. ET. Presentation webcasts will be accessible on Kymera's website, with archived replays available for 90 days.
Kymera Therapeutics (NASDAQ: KYMR) has announced a PIPE financing, issuing 2,769,228 shares of common stock at $26.00 each and pre-funded warrants for 3,000,000 shares at $25.9999. The anticipated gross proceeds of approximately $150 million will support ongoing R&D and general corporate needs. The financing is led by notable healthcare investors and is expected to close on August 22, 2022. Following the transaction, Kymera's cash reserves are projected to exceed $600 million by August 31, 2022.
Kymera Therapeutics (NASDAQ: KYMR) initiated dosing in Part C of its Phase 1 clinical trial for the IRAK4 degrader KT-474, aiming to share data by year-end 2022. The company has also launched Phase 1 trials for oncology programs KT-333 and KT-413, with results expected soon. As of June 30, 2022, Kymera reported a cash balance of approximately $482.5 million, providing a runway into 2025. Despite an increase in research and development expenses leading to a net loss of $40.3 million for Q2 2022, the company remains on track for significant clinical milestones this year.
Kymera Therapeutics, a clinical-stage biopharmaceutical company, is set to reveal its second quarter 2022 financial results on August 9, 2022. A conference call will follow at 8:30 a.m. ET, accessible via phone or a live webcast on their website. The company focuses on targeted protein degradation, utilizing its Pegasus platform to develop novel therapies for treating various immune-inflammatory diseases and cancers. Founded in 2016 and headquartered in Watertown, Mass., Kymera has gained recognition as an industry leader.
FAQ
What is the current stock price of Kymera Therapeutics (KYMR)?
What is the market cap of Kymera Therapeutics (KYMR)?
What is Kymera Therapeutics' main focus?
What is the Pegasus platform?
What are some key drugs in Kymera's pipeline?
What diseases is Kymera targeting?
What recent achievements has Kymera made?
How does Kymera's technology differ from conventional therapies?
Who are Kymera's partners?
Where is Kymera Therapeutics headquartered?
How is Kymera funded?
Where can I find more information about Kymera?
